class=" sacImgMarkCss">Figure S7. 160 Structures docked with RT.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] UNAIDS (2018) Fact Sheet—Latest Statistics on the Status of the AIDS Epidemic
http://www.unaids.org/en/resources/fact-sheet
[2] Hopkins, A.L., Ren, J., Milton, J., et al. (2004) Design of Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase with Improved Drug Resistance Properties. 1. Journal of Medicinal Chemistry, 47, 5912-5922.
https://doi.org/10.1021/jm040071z
[3] Freeman, G.A., Andrews III, C.W., Hopkins, A.L., et al. (2004) Design of Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase with Improved Drug Resistance Properties. 2. Journal of Medicinal Chemistry, 47, 5923-5936.
https://doi.org/10.1021/jm040072r
[4] Medina-Franco, J.L., Martínez-Mayorga, K., Juárez-Gordiano, C. and Castillo, R. (2007) Pyridin-2(1H)-ones: A Promising Class of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors. ChemMedChem, 2, 1141-1147.
https://doi.org/10.1002/cmdc.200700054
[5] Li, A., Ouyang, Y., Wang, Z., et al. (2013) Novel Pyridinone Derivatives as Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) with High Potency against NNRTI-Resistant HIV-1 Strains. Journal of Medicinal Chemistry, 56, 3593-3608.
https://doi.org/10.1021/jm400102x
[6] Tang, J., Maddali, K., Dreis, C.D., et al. (2011) N-3 Hydroxylation of Pyrimidine-2,4-diones Yields Dual Inhibitors of HIV Reverse Transcriptase and Integrase. ACS Medicinal Chemistry Letters, 2, 63-67.
https://doi.org/10.1021/ml1002162
[7] Tang, J., Maddali, K., Pommier, Y., Sham, Y.Y. and Wang, Z. (2010) Scaffold Rearrangement of Dihydroxypyrimidine Inhibitors of HIV Integrase: Docking Model Revisited. Bioorganic and Medicinal Chemistry Letters, 20, 3275-3279.
https://doi.org/10.1016/j.bmcl.2010.04.048
[8] Murray, J.M., Kelleher, A.D. and Cooper, D.A. (2011) Timing Of the Components of the HIV Life Cycle in Productively Infected CD4+ T Cells in a Population of HIV-Infected Individuals. Journal of Virology, 85, 10798-10805.
https://doi.org/10.1128/JVI.05095-11
[9] Maartens, G., Celum, C. and Lewin, S.R. (2014) HIV Infection: Epidemiology, Pathogenesis, Treatment, and Prevention. The Lancet, 384, 258-271.
https://doi.org/10.1016/S0140-6736(14)60164-1
[10] Vite-Caritino, H., Méndez-Lucio, O., Reyes, H., Cabrera, A., Chávez, D. and Medina-Franco, J.L. (2016) Advances in the Development of Pyridinone Derivatives as Non-Nucleoside Reverse Transcriptase Inhibitors. RSC Advances, 6, 2119-2130.
https://doi.org/10.1039/C5RA25722K
[11] Mendez-Lucio, O., Naveja, J.J., Vite-Caritino, H., Prieto-Martinez, F.D. and Medina-Franco, J.L., Review (2013) One Drug for Multiple Targets: A Computational Perspective. Journal of the Mexican Chemical Society, 60, 168-181.
[12] U.S. Department of Health and Human Services. Antiretroviral Drugs Used in the Treatment of HIV Infection. US Food and Drug Administration.
https://www.fda.gov/ForPatients/Illness/HIVAIDS/Treatment/ucm118915.htm
[13] Le Van, K., Cauvinz, C., de Walque, S., et al. (2009) New Pyridinone Derivatives as Potent HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors. Journal of Medicinal Chemistry, 52, 3636-3643.
https://doi.org/10.1021/jm801438e
[14] Dollé, V., Fan, E., Nguyen, C.H., et al. (1995) A New Series of Pyridinone Derivatives as Potent Non-Nucleoside Human Immunodeficiency Virus Type 1 Specific Reverse Transcriptase Inhibitors. Journal of Medicinal Chemistry, 38, 4679-4686.
https://doi.org/10.1021/jm00023a007
[15] Himmel, D.M., Das, K., Clark, A.D., et al. (2005) Crystal Structures for HIV-1 Reverse Transcriptase in Complexes with Three Pyridinone Derivatives: A New Class of Non-Nucleoside Inhibitors Effective against a Broad Range of Drug-Resistant Strains. Journal of Medicinal Chemistry, 48, 7582-7591.
https://doi.org/10.1021/jm0500323
[16] Chen, W., Zhan, P., Wu, J., Li, Z. and Liu, X. (2012) The Development of HEPT-Type HIV Non-Nucleoside Reverse Transcriptase Inhibitors and its Implications for DABO Family. Current Pharmaceutical Design, 18, 4165-4186.
https://doi.org/10.2174/138161212802430440
[17] Wang, Z. and Vince, R. (2008) Design and Synthesis of Dual Inhibitors of HIV Reverse Transcriptase and Integrase: Introducing a Diketoacid Functionality into Delavirdine. Bioorganic and Medicinal Chemistry, 16, 3587-3595.
https://doi.org/10.1016/j.bmc.2008.02.007
[18] Berman, H.M., Westbrook, J., Feng, Z., et al. (2000) The Protein Data Bank. Nucleic Acids Research, 28, 235-242.
https://doi.org/10.1093/nar/28.1.235
[19] Hare, S., Gupta, S.S., Valkov, E., Engelman, A. and Cherepanov, P. (2010) Retroviral Intasome Assembly and Inhibition of DNA Strand Transfer. Nature, 464, 232-236.
https://doi.org/10.1038/nature08784
[20] Molecular Operating Environment (MOE) (2014) Montreal, Quebec, Canada: Chemical Computing Group Inc.
https://www.chemcomp.com/
[21] Krusemark, C.J. (2012) Drug Design: Structure- and Ligand-Based Approaches. The Quarterly Review of Biology, 87, 165.
[22] Kerns, E.H. and Di, L. (2016) Drug-Like Properties: Concepts, Structure Design and Methods: From ADME to Toxicity Optimization. Academic Press, Amsterdam, 31.
[23] Radi, M., Falciani, C., Contemori, L., et al. (2008) A Multidisciplinary Approach for the Identification of Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: S-DABOCs and DAVPs. ChemMedChem, 3, 573-593.
https://doi.org/10.1002/cmdc.200700198
[24] Medina-Franco, J.L., Rodríguez-Morales, S., Juárez-Gordiano, C., Hernández-Campos, A., Jiménez-Barbero, J. and Castillo, R. (2004) Flexible Docking of Pyridinone Derivatives into the Non-Nucleoside Inhibitor Binding Site of HIV-1 Reverse Transcriptase. Bioorganic and Medicinal Chemistry, 12, 6085-6095.
https://doi.org/10.1016/j.bmc.2004.09.008
[25] Medina-Franco, J.L., Rodríguez-Morales, S., Juárez-Gordiano, C., Hernández-Campos, A. and Castillo, R. (2004) Docking-Based CoMFA And CoMSIA Studies of Non-Nucleoside Reverse Transcriptase Inhibitors of the Pyridinone Derivative Type. Journal of Computer Aided Molecular Design, 18, 345-360.
https://doi.org/10.1023/B:JCAM.0000047816.15514.ab

  
comments powered by Disqus
CMB Subscription
E-Mail Alert
CMB Most popular papers
Publication Ethics & OA Statement
CMB News
Frequently Asked Questions
Recommend to Peers
Recommend to Library
Contact Us

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.